Aurobindo Pharma's Board reappointed Ernst & Young LLP as Internal Auditor for FY27.
The reappointment is for a one-year term from June 2026 to May 2027.
The decision was made at a Board meeting held on May 21, 2026.
Disclosure is made pursuant to SEBI Listing Regulations Regulation 30.